[go: up one dir, main page]

EP0240550A1 - Proteines tensio-actives pulmonaires - Google Patents

Proteines tensio-actives pulmonaires

Info

Publication number
EP0240550A1
EP0240550A1 EP86906180A EP86906180A EP0240550A1 EP 0240550 A1 EP0240550 A1 EP 0240550A1 EP 86906180 A EP86906180 A EP 86906180A EP 86906180 A EP86906180 A EP 86906180A EP 0240550 A1 EP0240550 A1 EP 0240550A1
Authority
EP
European Patent Office
Prior art keywords
proteins
protein
sequence
dna
pulmonary surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP86906180A
Other languages
German (de)
English (en)
Other versions
EP0240550A4 (fr
Inventor
H. William Taeusch, Jr.
Kenneth A. Jacobs
D. Randall Steinbrink
Joanna Floros
Davis S. Phelps
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Genetics Institute LLC
Original Assignee
Brigham and Womens Hospital Inc
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, Genetics Institute LLC filed Critical Brigham and Womens Hospital Inc
Publication of EP0240550A1 publication Critical patent/EP0240550A1/fr
Publication of EP0240550A4 publication Critical patent/EP0240550A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to proteins isolated from human lung lavage, methods for obtaining said proteins and uses thereof.
  • Hyaline Membrane Disease and Respiratory Distress Syndrome (RDS) are synonymous terms denoting the clinical condition of pulmonary dysfunction in premature infants.
  • the disease is attributable to the absence of surface active material (surfactant) which lines the air-alveolar interface in the lung and prevents collapse of the alveoli during respiration.
  • surfactant surface active material
  • Current therapy is predominantly supportive.
  • bovine-derived surfactant into the lungs of the neonate.
  • pulmonary surfactant This complex consists of phospholipid and 5-10% protein (King, 1982).
  • the protein fraction of the surfactant is composed of nonserum and serum proteins.
  • the major surfactant associated protein is reportedly a 35,000 dalton nonserum, sialoglycoprotein (Shelly et al., 1982; Bhattacharyya et al, 1975; Sueishin and Benson 1981; King et al, 1973, Katyal & Singh, 1981). This protein reportedly seems to be important for the normal function of the pulmonary surfactant (King et. al., 1983; Hawgood et.al., 1985).
  • the present invention relates to a new group of proteins recovered and purified from lung lavage of patients with alveolar proteinosis, methods for obtaining the proteins, corresponding recombinant proteins, antibodies to the proteins for use in diagnostic products, compositions containing the novel proteins, and methods for using the compositions, e.g. in the treatment of infants afflicted with conditions such as Respiratory Distress Syndrome (RDS), as a drug delivery vehicle in the administration of other therapeutic materials to the lungs or other organs and in the treatment of adult RDS, which can occur during cardiopulmonary operations or in other situations when the lungs are filled with fluid and natural pulmonary surfactant production and/or function ceases.
  • RDS Respiratory Distress Syndrome
  • This invention relates to novel proteins useful for enhancing pulmonary surfactant activity, methods for obtaining said proteins and compositions containing one or more of the proteins.
  • the proteins of this invention include the following:
  • a protein characterized by a molecular weight of about 35 kd and by being encoded for by the DNA sequence depicted in Table 1.
  • a protein characterized by a molecular weight of about 35 kd and by being encoded for by the DNA sequence depicted in Table 2.
  • the proteins of this invention were obtained by subjecting pulmonary lavage material from an alveolar proteinosis patient to a combination of separation techniques followed by chromatographic purification. More specifically, the lavage material was centrifuged, and the protein-containing pellet so obtained was washed with buffer and extracted with a solvent such as 1-butanol to remove lipids and lipidassociated proteins. The butanol extract was set aside and treated as described below. The 1-butanol-insoluble material was then washed, redissolved in buffer and purified chromatographically. Two proteins were thus obtained which are characterized by a molecular weight of about 35 kd.
  • One of the 35 kd proteins is encoded for by the DNA sequence depicted in Table 1; the second 35 kd protein is encoded for by the DNA sequence depicted in Table 2.
  • Butanol-soluble proteins were obtained by cryoprecipitation. More specifically, storage of the 1-butanol extract at -20°C yielded a precipitate which was purified chromatographically to yield a protein characterized by an apparent molecular weight of about 6 kd (as determined by SDS-PAGE) and the observed amino acid composition set forth in Table 3.
  • a second 6 kd (as determined by SDS-PAGE) protein was obtained by concentrating the supernatant to dryness and purifying the residue chromatographically. The observed amino acid
  • composition of the latter 6kd protein is set forth in Table 4.
  • the two approximately 6kd proteins differ significantly from each other with respect to amino acid composition, as well as from the protein described by Tanaka, Chem. Pharm. Bull. 311:4100 (1983). Additionally, the N-terminal peptide sequence of the cold butanol-insoluble 6 kd protein was determined (Table 5). For the sake of simplicity, both low molecular weight PSP proteins are referred to hereinafter as "6k" proteins based on their approximate apparent molecular weights as determined by conventional SDS-PAGE. It should be understood, however, that the actual molecular weights of these proteins are in the range of 5.5-9 kilodaltons.
  • DNAs from two of these positive clones were subcloned into M13 for DNA sequencing, thus generating the clones MPSAP-1A and MPSAP-6A.
  • the nucleotide sequence for the cDNA clones encoding each of the two 35kd surfactant proteins was thereby elucidated and is presented above in Tables 1 and 2, respectively.
  • the sequences of subclones encoding the two 35 kd proteins are similar to each other but not identical.
  • the sequence differences result in restriction fragment polymorphism between the two clones with respect to the coding region recognized by the restriction enzyme Pstl. Considerably more nucleotide variation between the two clones was found in their 3' untranslated regions.
  • Plasmids PSP35K-1A-10 and PSP35K-6A-8 were constructed by inserting the approximately 940-950 nucleotide EcoRI fragments depicted in Tables 1 and 2, respectively, into the EcoRI site of plasmid SP65 (see infra).
  • PSP35K-1A-10 contains the polylinker site adjacent to the EcoRI site at cDNA position 1
  • PSP35K-6A-8 contains the polylinker site adjacent to the EcoRI site at cDNA position 947.
  • PSP35K-1A-10 and PSP35K-6A-8 have been deposited with the American Type Culture Collection (ATCC), Rockville, MD under accession Nos. ATCC 40243 and 40244, respectively.
  • oligonucleotide probes based on the N-terminal sequence of the cold butanol-insoluble 6K protein (See Table 5) were synthesized and were used to screen a cDNA library prepared from human lung mRNA (Tooie et al., 1984) as described in greater detail in Example 4, below. Several clones which hybridized to the probes were identified. Based on hybridization intensity one clone was selected, subcloned into M13 and sequenced. Plasmid PSP6K-17-3 was constructed by inserting the cloned cDNA so identified as an EcoRI fragment into the EcoRI site of plasmid SP65 (D.A.
  • PSP6K-17-3 has been deposited with the ATCC under accession No. ATCC 40245.
  • the nucleotide sequence of the cloned cDNA insert is shown in Table 6.
  • the cDNA insert in PSP6K-17-3 contains an open reading frame encoding a protein having a molecular weight of over 40kd. It is presently believed that the primary translation product is further processed, e.g., by Type II pneumocytes (Alveolar Type II cells), to yield the approximately 6K protein. It is contemplated that the cloned cDNA, portions thereof or sequences capable of hybridizing thereto may be expressed in host cells or cell lines by conventional expression methods to produce "recombinant" proteins having surfactant or surfactant enhancing activity.
  • this invention encompasses vectors containing a heterologous DNA sequence encoding the characteristic peptide sequence lie through Cys corresponding to nucleotides A-656 through C757 of the sequence shown in Table 6, i.e., IKRIQAMIPKGALAVAVAQVCRVVPLVAGGICQC.
  • One such vector contains the nucleotide sequence
  • vectors of this invention contain a heterologous DNA sequence encoding the characteristic peptide sequence substantially as depicted in the underlined peptide region of Table 6, i.e., FPIPLPYCWLCRALIKRIQAMIPKGALAVAVAQVCRWPLVAGGICQCLAERYSVILLDTLLGRML.
  • One such vector contains the DNA sequence substantially as depicted in the underlined nucleotide sequence of Table 6, i.e.,
  • Another exemplary vector contains a heterologous DNA sequence, such as the nucleotide sequence depicted in Table 6, which encodes the full-length peptide sequence of Table 6.
  • DNA inserts for such vectors which comprise a DNA sequence shorter than the full-length cDNA of PSP6K-17-3, depicted in Table 6, may be synthesized by known methods, e.g. using an automated DNA synthesizer, or may be prepared from the full-length cDNA sequence by conventional methods such as loop-out mutagenesis or cleavage with restriction enzymes and ligation. Vectors so prepared may be used to express the subject proteins by conventional means or may be used in the assembly of vectors with larger cDNA inserts. In the former case the vector will also contain a promoter to which the DNA insert is operatively linked and may additionally contain an amplifiable and/or selectable marker, all as is well known in the art.
  • the proteins of this invention may thus be produced by recovering and purifying the naturally-occuring proteins from human pulmonary lavage material as described herein.
  • the corresponding "recombinant" proteins may be produced by expression of the DNA sequence encoding the desired protein by conventional expression methodology using mi ⁇ robial or insect or preferably, mammalian host cells.
  • Suitable vectors as well as methods for inserting therein the desired DNA are well known in the art.
  • Suitable host cells for transfection or transformation by such vectors and expression of the cDNA are also known in the art.
  • Mammalian cell expression vectors for example, may be synthesized by techniques well known to those skilled in this art.
  • the components of the vectors such as the bacterial replicons, selection genes, enhancers, promoters, and the like may be obtained from natural sources or synthesized by known procedures. See Kaufman, Proc. Natl. A ⁇ ad. Sci. 82: 689-693 (1985).
  • Established cell lines including transformed cell lines, are suitable as hosts.
  • Normal diploid cells, cell strains derived from in vitro culture of primary tissue, as well as primary explants are also suitable.
  • Candidate cells need not be genotypically deficient in the selection gene so long as the selection gene is dominantly acting.
  • the host cells preferably will be established mammalian cell lines.
  • CHO (Chinese hamster Ovary) cells are generally preferred.
  • the vector DNA may include all or part of the bovine papilloma virus genome (Lusky et al., Cell, 36:391-401 (1984) and be carried in cell lines such as C127 mouse cells as a stable episomal element.
  • Other usable mammalian cell lines include HeLa, COS-1 monkey cells, mouse L-929 cells, 3T3 lines derived from Swiss, Balb-c or NIH mice, BHK or HaK hamster cell lines and the like.
  • Cell lines derived from Alveolar Type II cells may be preferred in certain cases such as expression of the 6K protein (alone or with one or more other proteins of this invention) using the cDNA insert from PSP6K-13-7 or a fragment thereof.
  • Stable transformants then are screened for expression of the product by standard immunological or enzymatic assays.
  • the presence of the DNA encoding the proteins may be detected by standard procedures such as Southern blotting.
  • Transient expression of the DNA encoding the proteins during the several days after introduction of the expression vector DNA into suitable host cells such as COS-1 monkey cells is measured without selection by activity or immunological assay of the proteins in the culture medium.
  • the DNA encoding the protein may be further modified to contain preferred codons for bacterial expression as is known in the art and preferably is operatively linked in-frame to a nucleotide sequence encoding a secretory leader polypeptide permittng bacterial secretion of the mature variant protein, also as is known in the art.
  • the compounds expressed in mammalian, insect or microbial host cells may then be recovered, purified, and/or characterized with respect to physicochemical, biochemical and/or clinical parameters, all by known methods.
  • One or more of the proteins of this invention may be combined with a pharmaceutically acceptable fatty acid or lipid such as dipalmitoylphosphatidyl choline or with mixtures of such fatty acids or lipids which may be obtained from commercial sources or by conventional methods, or with natural surfactant lipids to provide a formulated pulmonary surfactant composition.
  • Natural surfactant lipids may be extracted by known methods from lung lavage, e.g. bovine or human lung lavage. Typically the weight ratios of total lipids to total proteins in the composition will be about 20:1 to about 100:1. At the levels currently being tested in clinical trials, one dose of the surfactant composition corresponds to 1-2 mg of total protein and 98-99 mg. of total lipid.
  • Pulmonary lavage (50 ml) from an alveolar proteinosis patient was centrifuged at 10,000 x g for 5 min. The pellet was collected and washed 5 times in 20 mm Tris HCl, 0.5 M NaCl, pH 7.4. The lipids and lipid-associated proteins were extracted from the washed pellet by shaking with 50 ml 1-butanol for 1 hr at room temperature. The butanol-insoluble material was collected by centrifugation, washed with distilled water and dissolved in 50 mM sodium phosphate, pH 6.0 and 6M guanidine HCl.
  • the protein was applied to a Vydac C4 reverse phase column and eluted with a gradient of acetonitrile: 2-propanol (2:1,v:v) containing 0.1% trifluoroacetic acid.
  • the major protein peak eluting at 50% B was collected and evaporated to dryness.
  • the proteins present were analyzed by SDS-PAGE (Laemmli, 1970).
  • the protein so obtained (approx. 50ug) was taken up and reduced in 200mM Tris, 1mM EDTA, 6M guanidine HCl, 20mM DTT, pH8.5 at 37°C for 2 hrs. Solid iodacetamide was added to a final concentration of 60mM and the reaction incubated at 0°C for 2 hrs under argon in the dark. The reaction was stopped and the reagents removed by dialysis into 0.1M NH 4 HCO 3 , 50mM 2-mercaptoethanol, pH7.5 followed by further dialysis into 100mM NH 4 HCO 3 , pH7.5.
  • the alkylated protein was digested with trypsin (3% trypsin by weight) at 37°C for 16 hrs and the digest chromatographed over a C18 Vydac Reverse phase HPLC column (4.6x250mm).
  • the tryptic peptides were eluted with a linear gradient of 95% acetonitrile and 0.1% TFA, collected and subjected to N-terminal Edman degradation using an Applled-Biosystems Model 470A protein sequencer.
  • the PTH-amino acids were analyzed by the method of Hunkapillar and Hood (1983). Sequence data so obtained for tryptic fragments T19, T26 and T28 is presented below in Table 7.
  • the butanol extract obtained in Example 1 was stored at -20°C causing precipitation of one of the low MW proteins.
  • the precipitate was collected by centrifugation and dried under vacuum.
  • the butanol layer containing butanol-soluble protein was evaporated to dryness.
  • the precipitated cold butanol insoluble protein and the cold butanol-soluble protein were then purified in parallel by the same method as follows.
  • Each crude protein was separately dissolved in CHCl 3 : MeOH (2:1, v/v), applied to Sephadex LH20 columns and eluted with CHCl 3 :MeOH (2:1).
  • the proteins were then analyzed by SDS-PAGE. Fractions containing the protein were pooled and evaporated to dryness.
  • Amino acid composition was determined by hydrolysis in 6 N HCl at 110°C for 22 hrs followed by chromatography on a Beckman model 63000 amino acid analyzer. N-terminal sequence was determined on an Applied Biosystems 470A sequencer. Molecular weights were determined on 10-20% gradient SDS polyacrylamide gels.
  • oligonucleotide probe Based on the amino acid sequence of tryptic fragment T28, (Table 7) an oligonucleotide probe was synthesized. The probe consisted of four pools of 20 mers and each pool contained 32 different sequences. The sequences of the 20 mers are depicted in Table 8.
  • a cDNA library from human lung mRNA was prepared as described in Toole et al., (1984) and screened with the total mixture of the four pools using tetramethyl ammoniumchloride as a hybridization solvent (Jacobs et al., 1985) Between 0.5-1% of the phage clones were positive with this probe.
  • the two clones differed in nucleotide sequence at three positions out of 250 nucleotides. Both clones were completely sequenced by generating an ordered set of deletions with Bal 31 nuclease, recloning into other M13 vectors and sequencing via the dideoxynucletide chain termination procedure (Viera and Messing, 1982; Sanger et al., 1977).
  • One clone corresponded to a full-lenth copy of the type referred to as 1A (Table 1), the second to an incomplete copy of the type referred to as 6A (Table 2).
  • Table 1A the second to an incomplete copy of the type referred to as 6A
  • 6A Table 2
  • MPSAP-1A Very dilute (10-15 ug/ml) single stranded DNA from either subclone MPSAP-1A or MPSAP-1B was applied to nitrocellulose paper (10 ug/cm ) under vacuum (Kafatos et al., 1979).
  • MPSAP-IA represents the M13 subclone of a 0.9kb ECORI fragment in one orientation in M13.
  • MPSAP-1B represents the same fragment cloned in the opposite orientation in M13.
  • Each filter (1cm 2 ) was cut into nine equal size pieces and each piece was used in a 20-30ul hybridization reaction.
  • Each reaction contained human lung RNA (5mg/ml), 50% deionized formamide (Fluka AG Chemical Corp.), 10mM PIPES [(Piperazine-N, N'-bis) (2-ethanesulfonic acid)] pH 6.4 and 0.4M NaCl (Miller et al., 1983). The source and preparation of the RNA have been reported previously (Floros et al., 1985).
  • Each hybridization reaction was routinely incubated at 50°C for 3 hrs. At the end of the incubation period each filter was washed for five minutes with 1ml 1XSSC (.15M NaCl, 0.015M sodium citrate, 0.5% SDS at 60°C five times.
  • RNA was eluted by boiling for one minute in 300ul of ImM EDTA pH 7.9 and 10ug of yeast tRNA (Boehringer, Mannheim). The precipitated RNA was translated, immunoprecipitated and subjected to one and two dimensional gel electrophoresis as described in Floros et al., 1985.
  • an oligonucleotide probe was synthesized.
  • the probe consisted of six pools of 17 mers. Three of the pools each contained 128 different sequences, and three of the pools each contained 64 different sequences.Based on the first seven amino acids two pools of 20 mers were synthesized. These pools contained either 384 or 192 different sequences.
  • a cDNA library from human lung mRNA was prepared as described in Toole et al., (1984) and screened with the total mixture of the six pools using tetramethylammoniumchloride as a hybridization solvent (Jacobs et al., 1985). Approximately 100,000 phage were screened, and 100 phage which hybridized to the probe were plaque purified. The phage were then pooled into groups of 25 and screened with the individual 17 mer and 20 mer pools, six phage which hybridized most intensely to one of the 20 mer oligonucleotide probes and one of the corresponding 17 mer pools (pool 1447 containing 128 different sequences) were plaque purified.
  • the 17 mer pool 1447 was divided into four pools of 32 different sequences and hybridized to a dot blot of DNA prepared from these phage. Based on the hybridization intensity, DNA from one of these six phage were subcloned into M13 for DNA sequence analysis. A sequence corresponding in identity and position to the amino acids shown in Table 5 was obtained, confirming that the isolated clone coded for the approximately 6kd cold butanol-insoluble protein found in the lavage material of alveolar proteinosis patients (see above).
  • the first clone obtained was presumed to be an incomplete copy of the mRNA because it lacked an initiating methionine, and was used to isolate longer clones.
  • Two clones were completely sequenced by generating an ordered set of deletions with Bal 31 nuclease, recloning into other M13 vectors and sequencing via the dideoxynucleotide chain termination procedure (Viera and Messing, 1982; Sanger et al., 1977).
  • One clone corresponded to a full-length copy of the type referred to as 17 (Table 6), the second began at nucleotide 148 of clone 17.
  • Sequence of the 5' end of a third clone confirmed the sequence of the 5' end of clone 17.
  • the clones are identical throughout the coding region and differ only at two positions in the 3' untranslated region.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Nouvelles protéines destinées à améliorer l'activité tensio-active pulmonaire, procédés pour obtenir lesdites protéines et compositions contenant une ou plusieurs desdites protéines. Celles-ci se composent de deux protéines séparées caractérisées par un poids moléculaire d'environ 35 kd et de deux protéines séparées caractérisées par un poids moléculaire d'environ 5,5-9 kd.
EP19860906180 1985-09-26 1986-09-26 Proteines tensio-actives pulmonaires. Withdrawn EP0240550A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78113085A 1985-09-26 1985-09-26
US781130 1985-09-26
US89718386A 1986-08-15 1986-08-15
US897183 1986-08-15

Publications (2)

Publication Number Publication Date
EP0240550A1 true EP0240550A1 (fr) 1987-10-14
EP0240550A4 EP0240550A4 (fr) 1989-09-19

Family

ID=27119809

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19860906180 Withdrawn EP0240550A4 (fr) 1985-09-26 1986-09-26 Proteines tensio-actives pulmonaires.

Country Status (2)

Country Link
EP (1) EP0240550A4 (fr)
WO (1) WO1987002037A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013720A (en) * 1986-05-06 1991-05-07 Abbott Laboratories SAP-6-Val proteins and methods
EP0273916A4 (fr) * 1986-05-06 1989-11-30 Childrens Hosp Medical Center Proteine associee a un agent tensio-actif hydrophobe pulmonaire d'un poids moleculaire de 6000 daltons, et ses multimeres.
WO1988003170A1 (fr) * 1986-10-24 1988-05-05 Whitsett Jeffrey A Proteines associees a des agents tensioactifs hydrophobes pulmonaires
JPH01501282A (ja) * 1986-12-08 1989-05-11 ホイツトセツト，ジエフリー　エイ． 肺胞疎水性界面活性物質関連タンパク質
EP0313224A1 (fr) * 1987-09-28 1989-04-26 Children's Hospital Medical Center Lignées cellulaires humaines d'adénocarcinome épithélial pulmonaire, protéines humaines et méthodes
US5238920A (en) * 1989-08-22 1993-08-24 Abbott Laboratories Pulmonary surfactant protein fragments
DE69125750D1 (de) * 1990-05-21 1997-05-28 Abbott Lab Fettsäure-Oberflächenaktives-Lungenprotein Konjate
US5258496A (en) * 1990-07-10 1993-11-02 Scios Nova Inc. Isolation and purification of lung surfactant protein
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
US20060275274A1 (en) * 2003-03-26 2006-12-07 Daria Onichtchouk Use of saposin-related proteins for preventing and treating obesity, diabetes and/or metabolic syndrome
WO2009035395A1 (fr) 2007-09-14 2009-03-19 Marcus Larsson Produit surfactant pulmonaire

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411994A (en) * 1978-06-08 1983-10-25 The President And Fellows Of Harvard College Protein synthesis
ES506955A0 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
IE54046B1 (en) * 1981-08-25 1989-05-24 Celltech Ltd Expression vectors
JPS59164724A (ja) * 1983-03-10 1984-09-17 Tokyo Tanabe Co Ltd サ−フアクタント及びそれを含有する呼吸窮迫症候群治療剤
US4605627A (en) * 1983-06-07 1986-08-12 The Regents Of The University Of California Plasmid vehicle for cloning in Agrobacterium tumefaciens
JP2551746B2 (ja) * 1983-07-19 1996-11-06 サントリー株式会社 改良プラスミドベクタ−およびその利用
CS938384A1 (en) * 1983-12-08 1990-08-14 Lachmann Burkhardt Pharmaceutical agent for breathlesness therapy and method of its production
US4579321A (en) * 1983-12-30 1986-04-01 U.S. Amada Ltd. Positioner of compact type for working position in sheet or plate machining
US4933280A (en) * 1984-12-11 1990-06-12 California Biotechnology Inc. Recombinant DNA sequence encoding Alveolar Surfactant Protein
US4659805A (en) * 1984-12-11 1987-04-21 California Biotechnology, Inc. Recombinant alveolar surfactant protein
DE3688418T2 (de) * 1985-02-13 1993-08-26 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.

Also Published As

Publication number Publication date
WO1987002037A1 (fr) 1987-04-09
EP0240550A4 (fr) 1989-09-19

Similar Documents

Publication Publication Date Title
Jacobs et al. Isolation of a cDNA clone encoding a high molecular weight precursor to a 6-kDa pulmonary surfactant-associated protein.
JP2515468B2 (ja) ヒト抗トロンビンｉｉｉ
JP2882775B2 (ja) ヒトーグリア由来神経突起因子
AU648670B2 (en) A-C-B Proinsulin, method of manufacturing and using same, and intermediates in insulin production
US5362853A (en) Polypeptide derivatives of human granulocyte colony stimulating factor
JP3054192B2 (ja) 副甲状腺ホルモンの製造のための組換えｄｎａ法
KR100316347B1 (ko) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
US6025467A (en) Parathyroid hormone derivatives and their use
Liang et al. Studies of structure-activity relationships of human interleukin-2.
US6268180B1 (en) Recombinant human recombinant human interleukin-1α
US5795968A (en) Polypeptide derivatives of human granulocyte colony stimulating factor
WO1985001961A1 (fr) Production du facteur viii et des produits relatifs
WO1993020203A2 (fr) Variantes de l'hormone parathyroidienne a stabilite amelioree
AU3433189A (en) Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression
JP3217698B2 (ja) 成熟ヒト インターロイキン１タンパク質
US4918161A (en) Low molecular weight pulmonary surfactant proteins
EP0240550A1 (fr) Proteines tensio-actives pulmonaires
EP0182448A2 (fr) Production de facteur VIII et produits apparentés
US4882422A (en) Pulmonary surfactant proteins
EP0259891B1 (fr) Motiline [leu 13], molécules d'ADN encodant celle-ci, ainsi que ses méthodes de production
JP2807474B2 (ja) Ｄｎａおよびその用途
JPS6363199B2 (fr)
US5055553A (en) Low molecular weight pulmonary surfactant proteins
HU197939B (en) Process for producing deoxyribonucleic acid, or its precursor, determining human growth hormone releasing factor
US5656596A (en) Method of treating lesions in a nervous system

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19871009

A4 Supplementary search report drawn up and despatched

Effective date: 19890919

17Q First examination report despatched

Effective date: 19910809

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19930830

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TAEUSCH, H., WILLIAM, JR.

Inventor name: PHELPS, DAVIS, S.

Inventor name: JACOBS, KENNETH, A.

Inventor name: FLOROS, JOANNA

Inventor name: STEINBRINK, D., RANDALL